EDAP Sets Stage for Growth, Eyes Future Beyond Prostate Cancer

AUSTIN, Texas – May 13, 2026 – EDAP TMS SA (Nasdaq: EDAP), a pioneer in robotic energy-based therapies, has announced it will host a pivotal Investor Day on June 1, 2026. The event is poised to offer a detailed look into the company's strategic roadmap, but it comes at a time when EDAP is navigating a complex landscape of record-breaking revenue growth in its core division, widening financial losses, and ambitious plans to expand its technology into new medical frontiers.

The Austin-based company, known for its Focal One High-Intensity Focused Ultrasound (HIFU) system, intends to present its growth strategy, long-term financial targets, and plans for expanding therapeutic indications to an audience of analysts and investors. While the press release promises a forward-looking agenda, the company's recent performance paints a picture of a business in a crucial state of transition, doubling down on its high-margin technology while shouldering the costs of innovation and market expansion.

Riding the HIFU Revenue Wave

EDAP enters this investor event on the back of impressive, and strategically significant, financial results. The company's first-quarter 2026 earnings report highlighted a dramatic surge in its HIFU division, which is centered around the Focal One system for treating prostate cancer. HIFU revenue soared to $11.6 million, a remarkable 78.3% increase compared to the same period in 2025. This growth was fueled by the sale of 11 Focal One systems and a 30% jump in treatment-driven revenue, indicating not just wider adoption by hospitals but also increased utilization by physicians.

This performance continues a trend from the previous year. In 2025, EDAP achieved record full-year HIFU revenue of approximately $37.4 million, a 39% increase over 2024, driven by a 59% rise in system sales. This strategic shift towards the higher-margin HIFU business is evident, as the company's legacy distribution and ESWL (lithotripsy) segments now constitute a smaller portion of overall revenue. Management has reaffirmed its 2026 guidance, projecting HIFU revenue to grow by another 34% to 45%.

However, this aggressive growth strategy comes with substantial costs. Despite the revenue surge and an improved gross margin of 45.7% in Q1 2026, EDAP reported a net loss of $9.1 million for the quarter, widening from $7.4 million a year prior. The company's cash reserves have also dwindled, reflecting a significant cash burn from investments in its commercial infrastructure and research and development. While a recently secured €12 million credit facility provides near-term support, management acknowledges that substantial additional financing may be necessary to bridge the gap to profitability.

Redefining Prostate Cancer Care

The financial investments are directly tied to cementing Focal One's position as a new standard of care. The technology represents a paradigm shift away from the traditional all-or-nothing approach to prostate cancer, which often involves radical surgery (prostatectomy) or radiation, treatments that carry significant risks of life-altering side effects like incontinence and erectile dysfunction.

Focal One enables urologists to use real-time imaging and robotic precision to ablate, or destroy, only the cancerous tissue within the prostate, preserving the surrounding healthy structures. The clinical case for this less invasive approach has been powerfully reinforced by recent landmark studies. The HIFI study, a seven-year comparative trial involving over 3,300 patients, found that HIFU treatment (primarily with Focal One) was non-inferior to radical prostatectomy in terms of cancer control at 30 months. Critically, the study showed that quality-of-life outcomes were significantly better for HIFU patients, who experienced far less deterioration in urinary continence and erectile function.

Further bolstering its case, the HIFI-2 study demonstrated that Focal One is a viable salvage therapy for patients whose cancer returns after initial radiation treatment—a group with historically limited options. These robust clinical results are driving market adoption, with over 73 Focal One systems now installed in the U.S. and a growing number of hospital networks investing in multiple units.

A Strategic Path Through a Competitive Field

EDAP is not operating in a vacuum. The global market for High-Intensity Focused Ultrasound is projected to double to $2.6 billion by 2035, attracting numerous competitors. Key players like Insightec are advancing their own focused ultrasound systems, while alternative focal therapies such as NanoKnife (irreversible electroporation) offer different approaches to minimally invasive treatment. Furthermore, the market for prostate cancer treatment remains dominated by established players, including Intuitive Surgical's Da Vinci system for robotic-assisted radical prostatectomies.

Against this backdrop, EDAP's strategy appears to be one of deep focus and clinical validation. The company has successfully lobbied for better reimbursement, with a key victory in 2023 when the Centers for Medicare & Medicaid Services (CMS) significantly increased the payment rate for the HIFU procedure, making it a financially attractive option for U.S. hospitals. This, combined with the growing body of clinical evidence, is helping to move HIFU from an 'investigational' procedure to a mainstream treatment option listed in major clinical guidelines.

A Vision Beyond the Prostate

Perhaps the most anticipated topic for the upcoming Investor Day is the company's plan to expand its technology beyond prostate cancer. This strategic pillar is crucial for EDAP's long-term growth narrative and its ambition to become a broader platform in robotic energy-based therapies. The company has already made significant strides in this area.

Focal One has received CE Marking in Europe and, notably, a Breakthrough Device Designation from the U.S. FDA for the treatment of deep infiltrating rectal endometriosis, a painful and debilitating condition with few effective treatment options. A Phase 3 trial for this indication was recently completed, and the company is preparing to publish the full results. Success in this area would not only open a completely new market but also validate the versatility of the core technology.

Furthermore, EDAP has initiated a new clinical trial in France, dubbed 'PULS,' to evaluate the use of HIFU for treating pancreatic tumors, one of the most challenging and lethal forms of cancer. While this research is in its early stages, it signals a bold and ambitious vision for the future. The June 1st Investor Day will be a critical platform for the company's leadership to articulate how these initiatives fit into its financial projections and its ultimate goal of transforming patient care across multiple disease states.